83
Participants
Start Date
August 28, 2013
Primary Completion Date
April 26, 2019
Study Completion Date
April 26, 2019
Ceritinib
"LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients or mixed with water and given via nasogastric/gastric (NG/G) tube. For patients in fasted group: 1-2 tablespoons (15-30 mL) of an appropriate food such as apple sauce or non-fat yogurt and a glass of water were allowed.~For patients in the fed cohort: LDK378 was taken with, or within 30 minutes after finishing a low-fat light snack containing 100-300 calories and 1.5-2 grams of fat."
Novartis Investigative Site, Randwick
Novartis Investigative Site, Parkville
Novartis Investigative Site, Utrecht
Memorial Sloan Kettering SC - 7, New York
Novartis Investigative Site, Berlin
Novartis Investigative Site, Milan
Novartis Investigative Site, Madrid
Novartis Investigative Site, Essen
Novartis Investigative Site, Valencia
Novartis Investigative Site, Cologne
Novartis Investigative Site, Paris
Texas Children's Hospital Dept of Oncology, Houston
Novartis Investigative Site, Villejuif
Dana Farber Cancer Institute Dept of Onc, Boston
Cincinnati Children s Hospital Medical Center Dept of Oncology, Cincinnati
St Jude s Childrens Research Hospital Dept of Oncology, Memphis
Novartis Investigative Site, Toronto
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Rotterdam
Novartis Investigative Site, Seoul
Novartis Investigative Site, Barcelona
Novartis Investigative Site, West Midlands
Novartis Investigative Site, Sutton
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY